Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.
Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.
复制标题
慢性髓样白血病的口服治疗中的依从性轨迹：研究方案的概述。
DOI：
10.1002/nur.22069
复制
发表时间：
2020-09
影响因子：
2
通讯作者：
Jennings BM
中科院分区：
文献类型：
--
作者：
Yeager KA;Waldrop-Valverde D;Paul S;Bruner DW;Klisovic R;Burns E;Mason TA;Patel N;Jennings BM
现在超过四分之一的化疗方案包括口服药物。癌症患者现在有责任在家中按规定服用每一剂这种救命疗法。一种口服化疗，酪氨酸激酶抑制剂（TKIs），是目前慢性髓性白血病的推荐治疗方法。这种靶向治疗显著提高了生存率，但也带来了显著的副作用和经济成本。在本方案中描述的研究中，研究人员试图了解诊断为CML的个体所经历的TKI依从性的动态性质。在这项由国家癌症研究所资助的前瞻性观察性研究中，我们采用混合方法，试图描述受试者在一年内的依从性轨迹。我们的目标是使用基于模型的聚类分析来表征服用tki的个体的依从性轨迹。接下来，我们将确定副作用和财务毒性如何影响依从性轨迹。然后，我们将检查TKI依从性轨迹对疾病结局的影响。此外，我们将通过采访不同依从性轨迹的参与者子集来探索服用tki的患者的经验。预计样本包括120名服用tki的个体，我们将在12个月内每月评估他们，用客观测量（药物事件监测系统- MEMS®）测量依从性。识别tki的不同依从性轨迹对于发现最高不依从性风险的亚组非常重要，并将支持设计有针对性的干预措施。这项研究的结果可能会转化为其他口服药物，以改善对不同类型癌症的护理。
Over a quarter of chemotherapy regimens now include oral agents. Individuals living with cancer are now responsible for administering this lifesaving therapy at home by taking every dose as prescribed. One type of oral chemotherapy, tyrosine kinase inhibitors (TKIs), is the current recommended treatment for chronic myeloid leukemia. This targeted therapy has markedly improved survival but comes with significant side effects and financial costs. In the study described in this protocol, the investigators seek to understand the dynamic nature of TKI adherence experienced by individuals diagnosed with CML. Using a mixed method approach in this prospective observational study, funded by the National Cancer Institute, we seek to describe subjects’ adherence trajectories over one year. We aim to characterize adherence trajectories in individuals taking TKIs using model-based cluster analysis. Next, we will determine how side effects and financial toxicity influence adherence trajectories. Then we will examine the influence of TKI adherence trajectories on disease outcomes. Additionally, we will explore the experience of patients taking TKIs by interviewing a subset of participants in different adherence trajectories. The projected sample includes 120 individuals taking TKIs who we will assess monthly for 12 months, measuring adherence with an objective measure (Medication Event Monitoring System- MEMS®). Identifying differential trajectories of adherence for TKIs is important for detecting subgroups at the highest risk of nonadherence and will support designing targeted interventions. Results from this study can potentially translate to other oral agents to improve care across different types of cancer.
登录
查看更多内容
影响因子：
28.4
作者：
Dueck AC;Mendoza TR;Mitchell SA;Reeve BB;Castro KM;Rogak LJ;Atkinson TM;Bennett AV;Denicoff AM;O'Mara AM;Li Y;Clauser SB;Bryant DM;Bearden JD 3rd;Gillis TA;Harness JK;Siegel RD;Paul DB;Cleeland CS;Schrag D;Sloan JA;Abernethy AP;Bruner DW;Minasian LM;Basch E;National Cancer Institute PRO-CTCAE Study Group
通讯作者：
National Cancer Institute PRO-CTCAE Study Group
影响因子：
3.2
作者：
Hsieh, HF;Shannon, SE
通讯作者：
Shannon, SE
影响因子：
6.2
作者：
de Souza JA;Yap BJ;Wroblewski K;Blinder V;Araújo FS;Hlubocky FJ;Nicholas LH;O'Connor JM;Brockstein B;Ratain MJ;Daugherty CK;Cella D
通讯作者：
Cella D
影响因子：
1.3
作者：
Anderson, Kristin R.;Chambers, Carole R.;Sheikh, Naureen
通讯作者：
Sheikh, Naureen
影响因子：
1.8
作者：
Komarek, Arnost;Komarkova, Lenka
通讯作者：
Komarkova, Lenka